11 March 2023
Latham & Watkins Advises on BridgeBio Pharma’s Public Offering of Common Stock
Advising firms
Deal team
14 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Shayne Kennedy Lead | Latham & Watkins LLP | Partner | capital markets | Bay Area |
| Phillip Stoup Lead | Latham & Watkins LLP | Partner | capital markets | Bay Area |
| Casey Tong | Latham & Watkins LLP | Associate | capital markets | Not stated |
| Chelsi DeTurk | Latham & Watkins LLP | Associate | capital markets | Not stated |
| Amy Lutfi | Latham & Watkins LLP | Associate | capital markets | Orange County |
| Ben Haas | Latham & Watkins LLP | Partner | regulatory | Washington, D.C. |
| Betty Pang | Latham & Watkins LLP | Partner | regulatory | Bay Area |
| Nathan Beaton | Latham & Watkins LLP | Associate | regulatory | Washington, D.C. |
| Keira Murphy | Latham & Watkins LLP | Associate | regulatory | San Diego |
| Christopher Hazuka | Latham & Watkins LLP | Partner | IP | Bay Area |
| Rob Yeh | Latham & Watkins LLP | Associate | IP | San Diego |
| Kristina Funahashi | Latham & Watkins LLP | Associate | IP | San Diego |
| Grace Lee | Latham & Watkins LLP | Partner | tax | Bay Area |
| Alex Farris | Latham & Watkins LLP | Associate | tax | Not stated |
Stated terms
- Stated value
- USD 150m (US$150 million)
- What the figure measures
- Issue size
- Client
- Not stated
- Counterparties
- BridgeBio Pharma, Inc. (Issuer)